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Summary
Background Antitumour necrosis factor (anti-TNF)-a therapy has made a significant
impact on the treatment of psoriasis. Despite these agents being designed to neu-
tralize TNF-a activity, their mechanism of action in the resolution of psoriasis
remains unclear.
Objectives To understand better the mechanism of action of etanercept by examin-
ing very early changes in the lesional skin of patients with psoriasis responding
to etanercept.
Methods Twenty patients with chronic plaque psoriasis were enrolled and received
etanercept 50 mg twice weekly. Skin biopsies were obtained before treatment
and on days 1, 3, 7 and 14 post-treatment. Skin mRNA expression was analysed
by quantitative reverse-transcription polymerase chain reaction and microarray;
cytokine and phosphoprotein levels were assessed using multiplexed bead arrays.
Results In etanercept responders, we observed no significant changes in interleukin
(IL)-17A, IL-22 or interferon-c mRNA or protein in the first week of treatment;
however, there was a 25-fold downregulation of IL-17 receptor C (IL-17RC)
mRNA (P < 005) after day 1, accompanied by decreased extracellular signal-reg-
ulated kinase-1/2 phosphorylation. Transcriptional analysis revealed that genes
suppressed by etanercept significantly overlapped with IL-17A-induced genes,
and a marked overlap was also observed between the genes suppressed by etaner-
cept and by the anti-IL-17A agent ixekizumab. Finally we show that TNF-a
enhances the expression of IL-17RC, and short hairpin RNA inhibition of IL-17R
expression abrogates synergistic gene induction by TNF and IL-17A.
Conclusions These results suggest that the early responses of psoriasis plaques to eta-
nercept may be due to decreased tissue responsiveness to IL-17A due to sup-
pressed IL-17RC expression in keratinocytes, blunting the strong synergy between
TNF-a and IL-17, which contributes to the maintenance of psoriasis lesions.
What’s already known about this topic?
• Tumour necrosis factor (TNF)-a inhibitors are effective for the treatment of psoria-
sis, yet their mode of action appears to involve more than just inhibition of TNF-a
responses.
What does this study add?
• This study provides evidence that the early responses of psoriasis plaques to etaner-
cept may be due to diminished tissue responsiveness to interleukin (IL)-17A as a
result of the decreased expression of IL-17 receptor C.
• This effect blunts responses to T helper 17 cytokines and breaks a potentially self-
sustaining cycle that contributes to the maintenance of psoriasis lesions.
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Biologic agents targeting tumour necrosis factor (TNF)-a have
made a significant impact on the treatment of psoriasis, arthritis
and Crohn disease.1–3 Despite these agents being designed to
neutralize TNF-a activity, their mechanism of action in the
resolution of disease remains unclear. Psoriasis vulgaris is a
common inflammatory and hyperproliferative skin disease,
affecting over 4 million individuals.4 The most characteristic
feature of psoriasis is the marked hyperproliferation and altered
differentiation of epidermal keratinocytes. This epidermal
hyperproliferation is now thought to be driven largely by inter-
leukin (IL)-17A, IL-22, interferon (IFN)-c and TNF-a-secreting
T cells in the skin.5–8 It has been shown that the IL-17 cytokine
family members IL-17A, C and F are significantly elevated in
lesional psoriasis skin.9 These cytokines utilize a family of five
receptor subunits (IL-17RA to IL-17RE), all of which have been
detected in skin,9 with IL-17A and IL-17F using a combination
of IL-17RA and IL-17RC for signalling.9,10 The synergistic pro-
inflammatory activity of cytokines has recently become a focus
of attention,11–14 with an understanding that rather than acting
alone, each cytokine is participating in an inflammatory net-
work15–17 with the possibility that sequestration of one key
member of this network could result in the collapse of the net-
work and resolution of inflammation.
We propose that the mechanism of action of etanercept
involves dismantling the powerful synergy between TNF-a and
IL-17A, reducing IL-17A signalling and the expression of IL-
17A-induced chemokines prior to changes in T-cell numbers,
keratinocyte differentiation and proliferation. To test our
hypothesis, we analysed the expression of mRNA, cytokines and
phosphoproteins in the lesional skin of patients with chronic
plaque psoriasis being treated with the anti-TNF agent etaner-
cept twice weekly, focusing on the first 2 weeks of treatment
before improvements in disease severity were clinically evident.
Materials and methods
Study population
Twenty individuals with chronic plaque psoriasis were
enrolled (age range 18–75 years). Entry criteria included age
≥ 18 years and stable plaque-type psoriasis involving at least
10% body surface area (BSA). Exclusion criteria included use
of systemic psoriasis therapy within 4 weeks or topical ther-
apy within 2 weeks, or severe comorbid diseases. For
12 weeks, subjects received etanercept (Enbrel; Wyeth, Madi-
son, NJ, U.S.A.) 50 mg twice weekly subcutaneously. At base-
line, 6-mm punch biopsies were obtained under local
anaesthesia (lidocaine) from uninvolved skin and a target pla-
que. Subsequent biopsies were taken on days 1, 3, 7 and 14
of therapy from the same target plaque at least 1 cm away
from previous biopsy sites. Disease severity was recorded on
enrolment and at weeks 1, 2, 4 and 12 using percentage BSA
and Physician’s Global Assessment (PGA) scores. Informed
consent was obtained from all subjects, under protocols
approved by the Institutional Review Board of the University
of Michigan Medical School (HUM00037994). This study was
conducted in compliance with good clinical practice and
according to the Declaration of Helsinki principles.
Real-time quantitative reverse-transcription polymerase
chain reaction analysis
After removal from the skin, biopsies were bisected and snap
frozen in liquid nitrogen and stored at 80 °C until use.
Biopsies were pulverized with a hammer while still frozen,
dissolved in RLT buffer (Qiagen, Chatsworth, CA, U.S.A.),
homogenized using glass beads (Biospec Products Inc, Bartles-
ville, OK, U.S.A.) and total RNA was isolated (RNeasy Mini
Kit; Qiagen). A sample of 200 ng RNA was reverse transcribed
(High Capacity cDNA Transcription Kit; Applied Biosystems
Inc., Foster City, CA, U.S.A.) and transcripts quantified using a
7900HT Fast Real-Time polymerase chain reaction (PCR) sys-
tem (Applied Biosystems) using Taqman primer sets purchased
from Applied Biosystems (IL-17A, Hs00174383_m1; IL-22,
Hs00220924_m1; IL-17RA, Hs01064648_m1; IL-17RC,
Hs00994305_m1; IL-10RB, Hs00175123_m1; IL-22RA1,
Hs00222035_m1). All values were normalized to the expres-
sion of the housekeeping gene ribosomal protein, large, P0
(RPLP0, Hs99999902_m1).
RNA processing and microarray hybridization
Total RNA was isolated as above from biopsies from six indi-
viduals, quality checked using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, U.S.A.) and transcribed
for probe biotinylation using 5 lg RNA according to the man-
ufacturer’s protocols (Ambion, Austin, TX, U.S.A.). Six samples
were obtained from each individual, including two baseline
samples (psoriatic, PP and nonlesional, PN), as well as four
samples obtained following 1, 3, 7 and 14 days of etanercept
therapy, respectively (36 samples in total). Samples were run
on Affymetrix Human Genome U133 Plus 2.0 arrays, which
include 54 675 probe sets corresponding to 20 184 human
genes (Affymetrix, Foster City, CA, U.S.A.). CEL image files
were obtained for each sample, and posthybridization quality
control checks were performed using metrics appropriate for
Affymetrix gene chips [i.e. average background, intensity scale
factor, percentage probe sets called present, RNA degradation
score, relative log expression (RLE) median, RLE interquartile
range (IQR), normalized unscaled standard errors (NUSE)
median and NUSE IQR].18,19 Based on these analyses, a day-3
PP sample was removed for one patient, and a day-14 PP sam-
ple was removed for another, yielding a total of 34 samples
upon which further analyses were based. Normalization of
these 34 samples was then performed using the Robust Multi-
chip Average (RMA) method.20 The Wilcoxon signed-rank test
was also used to calculate the presence/absence of each of the
54 675 probe set features represented on the Affymetrix array
platform.21 Prior to further analyses, we removed 19 258
probe sets not expressed above background in at least 5% of
the 34 samples. This yielded 35 417 probe sets upon which
subsequent analyses were based. Raw microarray data have
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been deposited in the National Center for Biotechnology Infor-
mation Gene Expression Omnibus (GEO, http://www.ncbi.
nlm.nih.gov/geo) and are accessible through GEO series acces-
sion number GSE47751.
Statistics and gene set analyses
Data were tested for normality, and statistical significance was
calculated using the Student’s t-test, Mann–Whitney test or
Friedman test as appropriate, using GraphPad Prism version
5.00 for Windows (GraphPad Software, San Diego, CA,
U.S.A.). To evaluate the effects of etanercept on gene expres-
sion, paired moderated t-tests were carried out using the ‘lim-
ma’ package developed for the R statistical software.22 Four
separate analyses were performed in which lesional expression
in treated patients was compared with the baseline lesional
sample (i.e. day 1 vs. day 0, day 3 vs. day 0, day 7 vs. day 0,
day 14 vs. day 0; n = 5–6 for each comparison). To generate
ranked gene lists, results from these analyses were filtered to
remove redundant probe sets corresponding to the same
human gene.23 This was done by choosing a representative
probe set for each gene, corresponding to the probe set for
which the lowest P-value was obtained in the aforementioned
test for differential expression. Following this filtering, ranked
lists of genes were generated for each comparison, based on
the evidence for differential expression provided by raw P-val-
ues. Overlap between these lists and genes decreased in the
skin of ixekizumab-treated patients or genes induced by cyto-
kines in vitro was assessed using the hypergeometric distribu-
tion24 as recently described.25 For each analysis, the number
of overlapping genes between two ranked gene lists was com-
pared at different depths, with etanercept-decreased genes
compared with genes induced by IFN-c, IL-17, TNF-a or IL-
22 in cultured keratinocytes (GEO accessions GSE2737 and
GSE36287) or suppressed by ixekizumab (GSE31652) (Fig. S1;
see Supporting Information). This provided an idea of how
the number of genes belonging to the intersection region of a
Venn diagram would change when the top N genes were
selected and compared from two gene lists (with
10 < N < 2000). In addition to such comparisons, we identi-
fied Gene Ontology (GO) biological process terms enriched
among the 100 genes most strongly decreased by etanercept
following 14 days of therapy (i.e. day 14 vs. day 0; Fig. S2;
see Supporting Information), and we performed the same
analyses with respect to the 100 genes most strongly increased
by etanercept (Fig. S3; see Supporting Information). These
analyses were generated using the conditional hypergeometric
enrichment test procedure implemented in the GOstats pack-
age designed for the R statistical software.26
Multiplex bead assays
Biopsies were pulverized while still frozen, then suspended in
500 lL ice-cold lysis buffer (Bio-Rad, Hercules, CA, U.S.A.)
and ground in a glass tissue grinder. After one freeze–thaw
cycle, samples were centrifuged and supernatants collected
and diluted to 1 mg mL1 total protein in phosphate-buffered
saline. Bead assays were conducted as directed by the manu-
facturer (Bio-Plex; Bio-Rad) using duplicate 50-lL samples.
Concentrations were determined by four- or five-parameter
fitting of standard curves.
Keratinocyte culture
Normal human keratinocyte (NHK) cultures were established
from sun-protected adult human skin, as described,27 in
serum-free medium optimized for high-density keratinocyte
growth (Medium 154; Invitrogen, Portland, OR, U.S.A.).
NHKs were used for experiments in the second or third pas-
sage. All cells were plated at 5000 cells cm2 and maintained
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Fig 1. Clinical changes in disease severity were evident after 4 weeks of etanercept treatment. (a) On recruitment, the median body surface area
(BSA) was recorded as 35%. Overall 18/20 subjects responded to treatment with at least a 25% decrease in BSA by week 12 (Wk12), with a
mean decrease of 64% (range 26–99%). The two subjects with poor responses (0% and 17% reduction in BSA at week 12) were excluded from
further analysis as they were considered nonresponders. The decrease in disease severity was significant at week 4 and week 12 with respect to
BSA and Physician’s Global Assessment (PGA) scores (b). Boxes extend from the 25th to 75th percentiles showing the median as a line; whiskers
denote the 10th and 90th percentiles and dots show minimum and maximum values if outside this range. Statistical significance was determined
using the Friedman test (P < 0001, both series) with Dunn’s post-test on individual time points. *P < 005, **P < 001, ***P < 0001, n = 18.
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to 4 days postconfluence. Cultures were then starved of
growth factors in unsupplemented Medium 154 for 24 h
before use. NHKs were stimulated with recombinant human
TNF-a and IL-17A (R&D Systems, Minneapolis, MN, U.S.A.)
under low calcium (01 mmol L1) conditions.
Interleukin-17 receptor knock-down
shIL-17RA (shIL17RA-53; Sigma, St Louis, MO, U.S.A.) and
shIL17RC (shIL17RC-10; Sigma) pLKO.1-puro vectors (Sigma)
were grown in 293FT cells, and the constructs were tested for
knock-down of IL-17RA and IL-17RC expression, respectively,
as assessed by quantitative reverse-transcription (qRT)-PCR
and Western blotting using antibodies against IL-17RC (NBP1-
32481, 1 : 1000 dilution; Novus, Littleton, CO, U.S.A.) and
b-actin, to control for protein loading (clone AC-74, 1 : 2500
dilution; Sigma). The shIL17RA-53 and shIL17RC-10 con-
structs were selected for use in keratinocyte stimulation exper-
iments on day 2 postinfection, when knock-down was most
effective.
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Fig 2. Etanercept alters tissue cytokine and receptor mRNA expression in the first 2 weeks of treatment. Total RNA was extracted from snap-
frozen 6-mm punch biopsies of responding patients and analysed with quantitative reverse-transcription polymerase chain reaction. Transcripts for
interleukin (IL)-17A (a) and IL-22 (d) were significantly more abundant in lesional (day 0) than nonlesional skin (PN). During treatment, mRNA
for IL-17RC (c) but not IL-17RA (b) was significantly decreased. Neither IL-22 (d) nor its receptor subunits (e, f) were downregulated in the first
2 weeks of treatment. The decrease in IL-17RC preceded any changes in CD3+ T-cell infiltration (g) or human b-defensin 2 (HBD2) expression
(h). Statistical significance was determined with the Mann–Whitney test (PN vs. day 0) or Friedman test with Dunn’s multiple comparison test
(time course). Bars, mean + SEM, n = 18. *P < 005, **P < 001, ***P < 0001.
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Results
Clinical results
On recruitment, disease severity was recorded as a median BSA
of 35% and median PGA score of 36. We determined that 18
of 20 subjects were responders to treatment, defined as at least
a 25% decrease in BSA by week 12. The mean decrease in BSA
score was 64%, which was in accordance with our previous
study where 25 of 30 patients responded to etanercept with a
mean BSA decrease of 62%.28 The decrease in disease severity
was significant at weeks 4 and 12 with respect to both BSA and
PGA scores (Fig. 1a, b). Analyses of the two nonresponders
were underpowered to detect differences due to small sample
size, thus only responder data are presented in this report.
Etanercept alters tissue cytokine and receptor expression
Given that our hypothesis is that the mechanism of action of
etanercept involves early tissue responses that precede changes
in T-cell numbers, keratinocyte differentiation and prolifera-
tion, we first analysed cytokine mRNA expression by qRT-PCR
in the 18 responding patients. In the first 2 weeks of treat-
ment both IL-17A and IL-22 remained significantly elevated
compared with uninvolved skin, with IL-17A significantly
decreased only at day 14 (P < 005, Fig. 2a). Expression of
the IL-17A receptor subunit IL-17RA remained unchanged
(Fig. 2b); however, IL-17RC expression declined rapidly, with
significant decrease in expression observed already at day 1
(P = 00167 overall, Fig. 2c). This preceded any changes in
T-cell infiltration or human b-defensin 2 expression (Fig. 2g,
h). In contrast, neither of the receptor subunits for IL-22 were
altered in expression (Fig. 2e, f).
We also analysed tissue cytokine protein levels in the skin
biopsies using multiplex bead assays. Levels of IL-12p70, IL-
17A, IL-18, IFN-c, CXCL10 (induced protein-10), chemokine
(C–C motif) ligand (CCL)2 (monocyte chemoattractant pro-
tein-1), CCL3 [macrophage inflammatory protein (MIP)-1a],
CCL4 (MIP-1b) and CCL5 (RANTES) were all significantly
higher in lesional psoriasis (PP) biopsies than nonlesional skin
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Fig 3. Etanercept alters tissue cytokine protein expression in the first 2 weeks of treatment. Snap-frozen 6-mm punch skin biopsies were
pulverized and diluted to 1 mg mL1 total protein before analysis with Bio-Rad human cytokine multiplex kits. (a) Interleukin (IL)-12p70, (b)
IL-17A, (c) IL-18, (d) interferon (IFN)-c, (e) CXCL-10, (f) chemokine (C–C motif) ligand (CCL)2, (g) CCL3, (h) CCL4 and (i) CCL5 protein
levels were all determined to be significantly elevated in psoriasis plaques at day 0 (D0) compared with uninvolved skin (PN) from the same
individuals (Mann–Whitney test). During the first 7 days of treatment, CCL3 (g, P = 0039) showed a significant decline in protein levels
(Friedman test with Dunn’s multiple comparison test). Bars, mean + SEM, n = 5. *P < 005, **P < 001.
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(PN) at day 0 (Fig. 3). However, of these only IFN-c
(Fig. 3d, P = 0078, day 7) and CCL3 (Fig. 3g, P = 0039,
overall) showed a substantial decline in protein expression in
the first week of treatment.
Etanercept treatment results in decreased interleukin-17A
signalling
Given that we saw suppressed IL-17RC mRNA expression in
the psoriatic lesions, we examined events immediately down-
stream of cytokine receptors, using multiplex bead array assays
to examine the expression of the activated (phosphorylated)
forms of several important signal transduction molecules
downstream of the IL-17 receptor. We observed a 64%
decrease in the level of phospho-ERK1/2 on day 1 compared
with pretreatment; however, we detected no changes in the
levels of phospho-STAT3 (signal transducer and activator of
transcription 3) or phospho-Tyk-2 in skin (Fig. 4). This sug-
gests that in the first week of treatment there are no altera-
tions in the activity of type 1 interferons (via phospho-
STAT2) or IL-22 and IL-6 (and other cytokines that signal via
phospho-STAT3) in the skin.
Etanercept treatment is accompanied by decreased
interleukin-17A-induced gene expression in skin
Following RNA extraction, microarray analysis was performed
on skin biopsies taken from six individuals on days 1, 3, 7
and 14 of etanercept treatment. Using publicly available
datasets archived on GEO, specifically GEO series GSE31652,
GSE36287 and GSE7216 (Table S1; see Supporting Informa-
tion), we compared lists of genes most strongly downregulat-
ed by etanercept against lists of genes induced both by
treatment of NHKs with IL-17A, TNF-a, IFN-c and IL-22, and
by treatment of patients with psoriasis with the IL-17 inhibi-
tor ixekizumab (LY2439821). We found a significantly larger
than expected overlap between etanercept-decreased genes and
those genes induced by IL-17A on days 1, 7 and 14 (Fig. 5a).
Next, we compared a list of genes downregulated by etaner-
cept against those genes decreased by the IL-17 inhibitor
ixekizumab. We found a strong association between the genes
suppressed by etanercept and ixekizumab, which was evident
as early as day 1 of treatment and remained significant at each
time point tested (Fig. 5b). We also examined the overlap
between etanercept-decreased genes and lists of keratinocyte
genes induced by TNF-a (Fig. 5c), IFN-c (Fig. 5d) and IL-22
(Fig. 5e), with significant gene list overlaps only on day 1 of
treatment for TNF-a and IFN-c, and days 1, 7 and 14 for IL-
22-induced genes. This overlap between the top 1000 genes
most strongly decreased by etanercept and the top 1000 genes
most strongly altered by IL-17A, TNF-a, IFN-c, IL-22 and ix-
ekizumab is also depicted in an alternative graphic (Fig. S1;
see Supporting Information). Furthermore, we analysed the
genes most strongly altered by etanercept with respect to GO
biological processes, i.e. those genes increased or decreased in
day-14 lesions vs. those lesions obtained at baseline (Figs S2
and S3; see Supporting Information). Among the top 100
genes most strongly decreased in the day-14 lesions, we
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(d) (e) (f)
Fig 4. Extracellular signal-regulated kinase (ERK)1/2 (a), signal transducer and activator of transcription (STAT)2 (d) and, STAT3 (e), but not
p70 S6 kinase (b) or Tyk2 (f) are significantly activated in lesional skin compared with uninvolved skin. Snap-frozen 6-mm punch skin biopsies
were pulverized and diluted to 1 mg mL1 total protein before analysis with Bio-Rad human phosphoprotein multiplex kits. Tissue levels of
phospho-ERK1/2 (a) and phosphoglycogen synthase kinase (p-GSK)3a/b (c) were suppressed on days 1 and 7 after treatment with etanercept.
Bars, mean fluorescence  SEM, n = 5. Statistical significance determined with paired t-test. *P < 005, **P < 001.
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detected significant enrichment for GO terms such as response
to ‘type I interferon’, ‘leucocyte migration’ and ‘regulation of
T-cell apoptosis’ (false discovery rate < 005). These func-
tional terms are consistent with those associated with genes
most strongly elevated in psoriasis lesions (as compared with
normal uninvolved skin), suggesting that the effect of etaner-
cept is to shift gene expression patterns towards those in
normal skin.
Keratinocyte interleukin (IL)-17RA and IL-17RC are
induced by tumour necrosis factor (TNF)-a, and short
hairpin RNA knock-down of IL-17RA or IL-17RC abrogates
TNF-a–IL-17A synergism
Given that we observed a decrease in the expression of IL-
17RC in the skin of responders to etanercept, we tested the
effects of TNF-a on IL-17R expression by keratinocytes. NHKs
were treated with 0–10 ng mL1 TNF-a for 24 h and the
mRNA expression of the two receptor subunits IL-17RA and
IL-17RC was quantified by qRT-PCR. We found that while
TNF-a increased the expression of IL-17RA, the effect was
more pronounced for IL-17RC (Fig. 6a, b). The increased
expression of IL-17RC was confirmed using immunohisto-
chemical detection of IL-17RC in resting and TNF-a-treated
NHKs. After 24 h of TNF-a treatment, strikingly increased
immunofluorescence for IL-17RC could be seen (Fig. 6c).
To show how sequestering TNF-a by etanercept, leading to
a decrease in IL-17R expression, could lead to a decrease in
the expression of keratinocyte genes induced by the synergis-
tic activity of TNF-a and IL-17A, we selectively knocked down
IL-17RA or IL-17RC expression in NHKs using shRNA
(Fig. 6d, e). IL-17RA and IL-17RC mRNA expression was
TNF-α
IxekizumabIL-17A
IFN-γ IL-22
(a)
(c) (d) (e)
(b)
Fig 5. Etanercept treatment leads to suppression of interleukin (IL)-17-induced genes, and its effect overlaps with that of the anti-IL-17A biologic
ixekizumab. Following RNA extraction, microarray analysis was performed on skin biopsies taken from six individuals on days 1, 3, 7 and 14 of
etanercept treatment. We compared lists of genes downregulated by etanercept against a list of IL-17A-induced genes (a) or genes strongly
decreased by the IL-17 inhibitor ixekizumab (b) or genes induced by either tumour necrosis factor (TNF)-a (c) or interferon (IFN)-c (d). The
overlap between etanercept-decreased genes and IL-17A-induced genes (a) was significantly larger than expected at days 1, 7 and 14. There is a
strong association between etanercept-decreased genes and the genes most strongly decreased by the IL-17A inhibitor ixekizumab, even after only
1 day of treatment (b). The overlap between etanercept-decreased genes and those induced by TNF-a (c), IFN-c (d) or IL-22 (e) was much less
pronounced. In each box, the black line shows the level of overlap among the top n genes taken from each list, whereas the grey region outlines
the central 95% of the null distribution under a random sampling model (hypergeometric distribution). Larger than expected overlap (for given n)
is present if the line lies above the grey region, whereas lower than expected overlap (for given n) is present if the line lies below the grey
region. P-values are based on the overlap between the top 1000 genes from each gene list.
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suppressed to 9% and 4% of control levels, respectively
(Fig. 6d), and Western blotting revealed a strong suppression
in IL-17RC protein expression in shRNA-treated cells (Fig. 6e).
Keratinocytes with suppressed IL-17RA or IL-17RC expression
were stimulated with IL-17A in the presence of TNF-a to invoke
the synergistic induction of human b-defensin 2 (encoded by
DEFB4A), one of the most upregulated proteins in lesional
psoriasis skin. Knock-down of either receptor subunit, but
IL-17RC in particular, led to a significant suppression of TNF/
IL-17A-induced DEFB4A mRNA expression (Fig. 6f).
Discussion
The anti-TNF biologics etanercept, infliximab and adalimumab
have revolutionized the treatment of chronic skin disease over
the last 13 years, with disease remission rates (75% improve-
ment in Psoriasis Area and Severity Index) up to 80%,29–32
demonstrating that specific cytokine targeting can be extre-
mely effective in managing this disease. As such etanercept is
considered a first-line systemic biologic for chronic plaque
psoriasis. The anti-TNF biologics typically require a few weeks
before significant clinical improvement is noted,29–32 but early
studies on the mechanism of action of etanercept in psoriasis
have identified a number of changes in immune cell frequen-
cies33 and cytokine and chemokine mRNAs34 as early as
1 month into treatment, before any meaningful clinical
improvement has occurred, and more recent studies have
revealed biochemical and histological changes as early as
1 week into treatment.35,36 IL-1b and IL-8 expression was
shown to be decreased after 1 week,36 and interestingly this
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Fig 6. Tumour necrosis factor (TNF)-a induces interleukin (IL)-17R expression by keratinocytes, and short hairpin (sh)RNA knock-down of IL-
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occurred in patients who both did and did not respond to eta-
nercept treatment (about 30% of patients with psoriasis do
not respond well clinically).29 Using gene set enrichment
analysis it was further shown that both responders and nonre-
sponders to etanercept had decreases in TNF-a-induced genes,
but only responders had decreases in IL-17A-induced gene
sets.36 This suggests that control of IL-17A activity is a crucial
part of the mechanism of action of etanercept. In that respect,
etanercept has been shown to block TNF-a activation of mye-
loid dendritic cells leading to IL-23-driven Th17 responses.35
Moreover, IL-17A and TNF-a have been shown to have addi-
tive and synergistic effects directly on keratinocytes,11,28
which may be driven by the stabilization of TNF-a-induced
mRNA transcripts by IL-17A.37 Interestingly, the biology
behind the poor responses of the group of patients unrespon-
sive to etanercept is unknown, and there are still no reliable
predictors of clinical response.
IL-17 has been implicated in psoriasis for more than
15 years,14 and interest in this cytokine is now very strong
given the promising data from trials of anti-IL-17 biologics in
psoriasis.38–40 It is now widely appreciated that cytokines can
have strongly synergistic activities,11–14 working in a complex
inflammatory network15–17,41 promoting immune activation,
proliferation and inflammation. Thus we hypothesized that
etanercept acts by dismantling the powerful synergy between
TNF-a and IL-17, reducing IL-17 signalling and the expression
of IL-17-induced chemokines prior to later changes in T-cell
numbers, keratinocyte differentiation and proliferation
(Fig. 7). To test this idea, we took the approach of examining
very early time points in the treatment protocol to detect
some of the earliest biochemical changes that precipitate the
collapse of the inflammatory circuits that drive the psoriatic
hyperplasia.
We found that IL-17A, IL-22 and IFN-c mRNA and protein
showed no significant change in the first week of treatment
(Figs 2 and 3); however, there was a 25-fold downregulation
of IL-17RC mRNA after day 1 (Fig. 2c). In contrast, IL-17RA,
and subunits of the IL-22 receptor (IL-22RA and IL-10RB),
were unchanged (Fig. 2b, e, f). Examining the activation of
pathways downstream of these receptors showed reduction in
the phosphorylation of glycogen synthase kinase 3a/b and
ERK1/2 by 50% and 64%, respectively, on day 1, suggesting
reduced IL-17R signalling (Fig. 4). When we examined global
gene expression by microarray, we found that etanercept
induced a suppression of IL-17A-induced genes (Figs 5a and
S1), which is consistent with the findings of Zaba et al.,42 who
found that IL-17 pathway genes were strongly downregulated
in etanercept responders. Moreover, this etanercept-suppressed
gene set overlapped with those genes suppressed by the anti-
IL-17A drug ixekizumab (Fig. 5b). Moreover, TNF-a was
shown to increase the expression of IL-17RC mRNA and pro-
tein by keratinocytes (Fig. 6a–c), and shRNA inhibition of IL-
17RC expression curtailed synergistic TNF–IL-17A responses
(Fig. 6d–f). As IL-17A utilizes the IL-17RA–IL-17RC complex
for signalling, the decreased expression of IL-17RC induced by
etanercept is likely to lead to decreased keratinocyte activation
by IL-17A, with subsequent decreases in T-cell and antigen-
presenting-cell activity,28,35,36 and an eventual decrease in
disease activity resulting in resolution of skin inflammation
(Fig. 7). Along these lines, the recent data on the efficacy of
biologics targeting both IL-17A38,39 and its IL-17RA receptor
chain40 highlight the crucial role of IL-17A in psoriatic
inflammation. Moreover, given the need for IL-17RC in the
IL-17R complex, agents targeting IL-17RC may also hold the
promise of efficacy for psoriasis and Th17-driven inflamma-
tory diseases.
In conclusion, these results support the view that the early
responses of psoriasis plaques to etanercept are due to
decreased IL-17A activity, not from lowered Th17 cytokine
expression, as the lesions are still rich in IL-17A, IL-22 and
activated STAT3. Instead, response to etanercept is due to
diminished tissue responsiveness to IL-17A as a result of
decreased expression of an essential subunit of the IL-17A
receptor (IL-17RC), thus blunting responses to Th17 cytokines
and breaking a potentially self-sustaining cycle that contributes
to the maintenance of psoriasis lesions.
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Fig 7. A proposed model of action of etanercept in psoriasis lesions.
Tumour necrosis factor (TNF)-a and interleukin (IL)-17A are integral
parts of a self-sustaining proinflammatory cytokine network that
maintains psoriatic lesions. We hypothesized that etanercept acts by
dismantling the powerful synergy between TNF-a and IL-17
(a):11,28,37 by reducing keratinocyte IL-17 receptor expression (b); by
decreasing IL-17 signalling (c) and by decreasing the induction of IL-
17-induced chemokines (d), all prior to changes in T-cell (red),
antigen presenting cell (APC, green) and neutrophil (purple) numbers
in skin (e), and keratinocyte differentiation and proliferation (f). EBP,
enhancer-binding protein; ERK, extracellular signal-regulated kinase;
GSK, glycogen synthase kinase; IKB, inhibitor of jB; TNFR, TNF
receptor.
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